• Archer granted a key US patent for its Biochip project to protect its IP rights in the US
• The patent grant protects Archer's Biochip technology IP and allows the Company to explore opportunities to work with medical device partners in the US
• The patent represents the design and work done on the graphene complexes and their compositions that can be used in the Biochip

Archer Materials Limited ('Archer', the 'Company', 'ASX: AXE'), a semiconductor company advancing the quantum technology and medical diagnostics industries, has been granted a key patent in the United States of America ('US Patent') associated with Archer's Biochip technology, protecting the Company's related intellectual property ('IP') rights in the US. The US Patent (Patent No. 12202730) represents the work done in Archer's development of the biosensing chip for graphene complexes and their compositions that can be used in biomolecular sensing. The Company considers the US as a critical strategic jurisdiction to protect and potentially commercialise its Biochip IP. Patent protection in the US is required for any future commercialisation operations in the US, and also provides Archer with access to the world's largest economy to exploit IP rights related to the Biochip. Graphene is a form of carbon and possesses a number of useful attributes, including low molecular mass, extremely large surface area, high thermal and electrical conductivity, and exceptional mechanical strength. However, one limitation preventing the widespread use of graphene is its chemical robustness, with difficulties in attaching inorganic molecules to the graphene surface. To overcome this challenge and unlock graphene potential (especially for biological sensing applications) new methods to attach inorganic molecules to graphene are needed. Archer has been researching new ways to address this challenge and with the granting of the US Patent, Archer's IP is now protected. Archer has been successful in patenting new methods of modifying graphene surface for more complex chemical reactions, involving inorganic compounds with high thermal, oxidative and chemical stabilities. Archer believes that new graphene complexes and their compositions will play a significant role in the success of the Biochip.

The grant of the US patent is a critical milestone for the Biochip program and bolsters Archer's expanding intellectual property portfolio and provides enhanced protection for its Biochip program aimed at detecting potassium in blood. The US represents a key market for the sale of Archer's Biochip in time, due to the size of the market and the rate of chronic kidney disease in the country.